How Crizotinib 250mg Benefits ALK-Positive Lung Cancer Patients and Why It Drives Franchise Interest
The management of lung cancer has shifted with the advent of targeted therapies. Rather than applying the same therapeutic module per patient, there has been a growing trend in modern-day clinical oncology to focus on specific genetic alterations that may be responsible for the tumor growth. Crizotinib 250 mg is a targeted drug used in […]